The drug exhibits a multimodal mechanism. It not only reverses chemoresistance and halts tumor growth but also 'turns cold tumors hot' by forcing cancer cells to display markers that make them visible to the immune system. This dual action of direct attack and immune activation creates a powerful synergistic effect.

Cancer cells down-regulate microRNAs to enable growth. This biological shift creates an opening for Nuago's therapy to access the cell's machinery. Healthy cells, with high microRNA expression, naturally block the therapy. This provides inherent selectivity, a huge therapeutic window, and minimal toxicity by design of fundamental biology.

Cancer should be viewed not just as rogue cells, but as a complex system with its own supply chains and communication infrastructure. This perspective shift justifies novel therapies like Zelenorstat, which aim to dismantle this entire operating system by cutting its power source.

Unlike therapies targeting a single cell death pathway like apoptosis, Nuago's DICE (Death Induced by Survival Gene Elimination) triggers a systemic collapse. By silencing numerous survival genes, it disrupts core cellular networks, activating all 22 known molecular cell death pathways at once, making it impossible for the cancer cell to escape.

Traditional targeted cancer therapies inhibit or 'cool down' overactive pathways, like pumping brakes on a runaway car. Delpha Therapeutics employs a counterintuitive 'activation lethality' approach, further over-activating pathways to 'overheat the engine' and cause catastrophic failure in cancer cells—a fundamentally opposite but highly effective strategy.

Instead of screening vast libraries of compounds against a target, Hamlet first uses genome-wide and proteomic analysis to understand the core molecular basis of a disease. Only after defining the problem do they search for molecules to inhibit that specific disease pathway, letting the experiment guide them to the solution.

Instead of just killing cancer cells, the primary mechanism is to insert a gene that forces the infected cell to produce and secrete a potent drug, like an anti-PD-L1 antibody. This creates a hyper-concentrated therapeutic effect directly in the tumor microenvironment, a concept termed "molecular surgery."

Instead of developing new antibiotics, Hamlet identifies the molecular basis of a patient's sickness and creates molecules to shut off that specific response. This makes the treatment effective against both resistant and sensitive bacteria, representing a paradigm shift in treating infectious diseases.

Earli's technology delivers a genetic blueprint, not a drug. A lipid nanoparticle inserts a DNA-based "switch" that programs cancer cells to produce complex therapeutic payloads locally. This solves the dual problems of systemic drug dilution and off-tumor side effects, aiming to significantly raise the therapeutic index for potent therapies.